Sign inJoin waitlistJoin the waitlist

AK

Andrew Kin

Physician · Wayne State University School of Medicine

Credentials: · · · · · ·

History

Wayne State University School of Medicine
Present

Hematology and Medical Oncology
2015–2018
Internal Medicine
Ohio State University Hospital
2012–2015
University of Cincinnati College of Medicine
2008–2012

Research

Daratumumab proves safe and highly effective in AL amyloidosis
British Journal of Haematology · 2019 · 45 citations
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual…
JAMA Oncology · 2022 · 33 citations
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma
Future Oncology · 2023 · 16 citations

Jeffrey Zonder
8 papers
Abinhav Deol
6 papers
DM
Dipenkumar Modi
6 papers
Joseph Uberti
6 papers
Lois Ayash
6 papers
VR
Voravit Ratanatharathorn
6 papers
Asif Alavi
5 papers
Ajay Major
4 papers · 2 as a fellow
AJ
Andrzej Jakubowiak
3 papers
Angela Dispenzieri
3 papers
Ben Derman
3 papers
CS
Caitlin Sarubbi
3 papers · 3 as a resident

Clinical trials

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2024–2030
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2022–2028
DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
Sub-investigator · Recruiting · Phase 2
Barbara Ann Karmanos Cancer Institute
2024–2028
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Sub-investigator · Recruiting · Phase 2
Barbara Ann Karmanos Cancer Institute
2023–2028